Alpha Tau CEO reviews year's scientific and regulatory progress
The letter highlights clinical trial successes, FDA approvals, and a Barclays price target increase.
Latest Alpha Tau Medical News & Updates
See the latest news and media coverage for Alpha Tau. We track all announcements, press releases, and industry mentions in real time, all in one place.
Clinical-stage oncology company developing alpha radiation therapy
alphatau.com- Headquarters
- Jerusalem , Israel
- Founded year
- 2016
- Company type
- Private company
- Number of employees
- 100–200
- Industry
- Biotechnology & Medical Research
Last updated
Latest news about Alpha Tau Medical (Alpha Tau)
In short: Alpha Tau achieved significant clinical results in brain and skin cancer trials, received Japanese approval, and partnered with Tolmar.
Company announcements
Alpha Tau completes enrollment in pancreatic cancer pilot study
The IMPACT trial reached 48 patients across expanded sites, with results expected in early 2027 to guide a global pivotal program.
Alpha Tau presents early Alpha DaRT plus immunotherapy results
In an interview, Prof. Aron Popovtzer discusses a nine-patient study showing 100% objective response, including four complete responses, and an observed abscopal effect in an untreated tumor.
Alpha Tau reports Q2 2026 results and corporate update
The company reported a $68.8 million net loss, $104.8 million cash balance, and Tolmar collaboration for prostate cancer, with multiple clinical milestones.
Media coverage
Alpha Tau's Cancer Trials Keep Beating Expectations. Three Major Data Readouts Are Next.
WSW, NY, September 15th, 2026, FinanceWireA head and neck cancer trial was stopped early because the results were so strong...
Alpha Tau Completes Patient Enrollment in its Multicenter IMPACT Pancreatic Cancer Pilot Study of Alpha DaRT® Following Strong Demand and Multiple Expansions
IMPACT, a multicenter pilot study of Alpha DaRT® for newly diagnosed unresectable pancreatic cancer, expanded enrollment three times over the...
Hadassah performs first-ever alpha radiation treatment for recurring brain tumors
The technology, which emits highly bioefficient alpha particles that deliver concentrated radiation, was developed in collaboration with the Sharett Institute of Oncology and ALPHA Tau.
Alpha Tau Announces Second Quarter 2026 Financial Results and Provides Corporate Update
- Groundbreaking interim results from the U.S. recurrent glioblastoma REGAIN trial demonstrated 100% local disease control and a 67% complete response rate, followed by FDA...
Never miss news about Alpha Tau
Track Alpha Tau and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Trending companies
Discover what's making headlines across other trending companies.